May your metabolic health stay optimized, your weight management stay sustainable, and your supplement choices stay evidence-based.
Studies published in English that directly assessed misleading, false, or unsupported claims were included
The US Food and Drug Administration approved Wegovy for weight loss in the summer of 2021 and Zepbound for weight loss in the fall of 2023
In the case of compounded semaglutide, the pharmacy may combine semaglutide with other ingredients, such as vitamins or minerals, to create a medication that is tailored to the specific needs of the patient
Weight loss is the most visible change, with clinical trials demonstrating average reductions that vary by medication: approximately 5-10% with liraglutide (Saxenda), 15-17% with semaglutide 2.4mg (Wegovy) in the STEP trials, and up to 20% with higher doses of tirzepatide in the SURMOUNT programme
Launch Your Weight Loss Clinic in Michigan Today